Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, Iressa R) and chemotherapeutic agents in human lung cancer cells

Carcinogenesis

Volumn 29, Issue 7, 2008, Pages 1448-1458

  Ko, Jen Chung ^a   Ciou, Shih Ci ^a   Cheng, Chau Ming ^a   Wang, Lyu Han ^a   Hong, Jhao Hao ^a   Jheng, Ming Yan ^a   Ling, Szu Ting ^a   Lin, Yun Wei ^a  

^a NATIONAL CHIAYI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MITOMYCIN C; RAD51 PROTEIN; ZD 1830;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL DEATH; CELL PROTECTION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUNG CANCER; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG SYNERGISM; HUMANS; LUNG NEOPLASMS; MAP KINASE KINASE 1; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOMYCIN; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RAD51 RECOMBINASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; TRANSFECTION;

EID: 49349094037     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgn130     Document Type: Article

References (74)

1. Silvestri,G.A. et al. (2005) Targeted therapy for the treatment of advanced non-small cell lung cancer: A review of the epidermal growth factor receptor antagonists. Chest, 128, 3975-3984.
2. Landis,S.H. et al. (1999) Cancer statistics, 1999. CA Cancer J. Clin., 49, 8-31, 1.
3. Pfister,D.G. et al. (2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J. Clin. Oncol., 22, 330-353.
4. Schiller,J.H. et al. (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346, 92-98.
5. Salomon,D.S. et al. (1995) Epidermal growth factor-reldled pcptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol., 19, 183-232.
6. Arteaga,C.L. (2003) EGF receptor as a therapeutic target: Patient selection and mechanisms of resistance to receptor-targeted drugs. J Clin. Oncol., 21, 289s-291s.
7. Raymond,E. et al. (2000) Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy, Drugs, 60 (suppl. 1), 15-23; discussion, 41-42.
8. Morin,M.J. (2000) From oncogene to drug: Development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents. Oneogene, 19, 6574-6583.
9. Gilmore,A.P. et al. (2002) Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J. Biol. Chem., 277, 27643-27650.
10. Mendelsohn,J. (2001) The epidermal growth factor receptor as a target for cancer therapy. Endocr. Relat. Cancer, 8, 3-9.
11. Wakeling,A.E. et al. (2002) ZD 1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res., 62, 5749-5754.
12. Sridhar,S.S. et al. (2003) Inhibitors of epidermal-growth-factor receptors: A review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol., 4, 397-406.
13. Lynch,T.J. et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 350, 2129-2139.
14. Rosell,R. et al. (2006) Epidermal growth factor receptor activation: How exon 19 and 21 mutations changed our understanding of the pathway. Clin. Cancer Res., 12, 7222-7231.
15. Furuta,T. et al. (2002) Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res., 62, 4899-4902.
16. Scagliotti,G. (2007) Optimizing chemotherapy for patients with advanced non-small cell lung cancer. J. Thorac. Oncol., 2 (suppl. 2), S86-S91.
17. Rockwell,S. et al. (1993) Cellular pharmacology of quinone bioreductive alkylating agents. Cancer Metastasis Rev., 12, 165-176.
18. Booton,R. et al. (2006) A phase III trial of docetaxel/ carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/ vinblastine/cisplatin (MVP) in-patients with advanced non-small-cell lung cancer. a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann. Oncol., 17, 1111-1191.
19. Babiak,A. et al. (2007) Mitomycin C and vinorelbine for second-line chemotherapy in NSCLC-a- phase II trial. Br J. Cancer, 96, 1052-1056.
20. Shinohara,A. et al. (1992) Rad51 protein involved in repair and recombination in S. cerevisiae is a RecA-like protein. Cell, 69, 457-470.
21. Haaf,T. et al. (1995) Nuclear foci of mammalian Rad51 recombination protein in somatic cells after DNA-damage and its localization in synaptonemal complexes. Proc. Natl Acad. Sci. USA, 92, 2298-2302.
22. Tashiro,S. et al. (1996) S phase-specific formation of the human Rad51 protein nuclear foci in lymphocytes. Oncogene, 12, 2165-2170.
23. Maacke,H. et al. (2000) Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int. J. Cancer, 88, 907-913.
24. Yoshikawa,K. et al. (2000) Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas. Int. J. Cancer, 88, 28-36.
25. Vispe,S. et al. (1998) Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res., 26, 2859-2864.
26. Amaudeau,C. et al. (1999) The RAD51 protein supports homologous recombination by an exchange mechanism in mammalian cells. J. Mol. Biol., 289, 1231-1238.
27. Qiao,G.B. et al. (2005) High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br. J. Cancer, 93, 137-143.
28. Takenaka,T. et al. (2007) Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int. J. Cancer, 121, 895-900.
29. Schneider,S. et al. (2006) Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation. Pharmacogenet. Genomics 16, 555-563.
30. Chang,L. et al. (2001) Mammalian MAP kinase signalling cascades. Nature, 410, 37-40.
31. Kolch,W. (2005) Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat. Rev. Mol. Cell Biol., 6, 827-837.
32. Galanis,A. et al. (2001) SelectiNe targeting of MAPKs to the ETS domain transcription factor SAP-1. J. Biol. Chem., 276, 965-973.
33. Murphy,L.O. et al. (2004) A network of immediate early gene products propagates subtle differences in mitogen-activated protein kinase signal amplitude and duration. Mol. Cell. Biol., 24, 144-153.
34. Kolch,W. (2000) Meaningful relationships: The regulation of the Ras/Raf/ MEK/ERK pathway by protein interactions. Biochem. J., (351 Pt), 2, 289-305.
35. Marshall,C.J. (1995) Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell, 80, 179-185.
36. Lin,Y.W. et al. (2003) ERK1/2 achieves sustained activation by stimulating MAPK phosphatase-1 degradation via the ubiquitin-proteasome pathway. J. Biol. Chem., 278, 21534-21541.
37. Lin, Y.W. et al. (2003) Persistent activation of ERK1/2 by lead acetate increases nucleotide excision repair synthesis and confers anti-cytotoxicity and anti-mutagenicity. Carcinogenesis, 24, 53-61.
38. Peters,G.J. et al. (2000) Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol. Ther., 87, 227-253.
39. Bennett,B.T et al. (2005) Cellular localization of human Rad51C and regulation of ubiquitin-mediated proteolysis of Rad51. J. Cell. Biochem., 96, 1095-1109.
40. Ciardiello,F. et al. (2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res., 6, 2053-2063.
41. Sirotnak,F.M. et al. (2000) Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res., 6, 4885-4892.
42. Ciardiello,F. (2000) Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs, 60 (suppl. 1), 25-32; discussion, 41-42.
43. Ono,M. et al. (2004) Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol. Cancer Ther., 3, 465-472.
44. Kris,M.G. et al. (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290, 2149-2158.
45. Spira,A. et al. (2004) Multidisciplinary management of lung cancer. N. Engl. J. Med., 350, 379-392.
46. Yaneva,J. et al. (1997) The major chromatin protein historic H1 binds preferentially to cis-platinum-damaged DNA. Proc. Natl Acad. Sci. USA, 94, 13448-13451.
47. Benhar,M. et al. (2001) Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Mol. Cell. Biol., 21, 6913-6926.
48. Gatzemeier,U. et al. (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol., 25, 1545-1552.
49. Giaccone,G. (2004) The role of gefitinib in lung cancer treatment. Clin. Cancer Res., 10, 4233s-4237s.
50. Herbst,R.S. et al. (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J. Clin. Oncol., 22, 785-794.
51. Herbst,R.S. et al. (2005) TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23, 5892-5899.
52. Giovannetti,E. et al. (2008) Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol. Pharmacol., 73, 1290-1300.
53. Verweij,J. et al. (1990) Mitomycin C: Mechanism of action, usefulness and limitations. Anticancer Drugs, 1, 5-13.
54. Dorr,R.T. et al. (1985) Interactions of mitomycin C with mammalian DNA detected by alkaline elution. Cancer Res., 45, 3510-3516.
55. Feliu,J. et al. (2006) Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer. Cancer Chemother. Pharmacol., 58, 527-531.
56. Kelland,L. (2007) The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer, 7, 573-584.
57. Zamble,D.B. et al. (1996) Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry, 35, 10004-10013.
58. Wei,Q. et al. (2000) DNA repair: A double-edged sword. J. Natl Cancer Inst., 92, 440-441.
59. Stewart,D.L. (2007) Mechanisms of resistance to cisplatin and carboplatin. Crit. Rev. Oncol. Hematol., 63, 12-31.
60. Camps,C. et al. (2007) Gene expression and polymorphisms of DNA repair enzymes: Cancer susceptibility and response to chemotherapy. Clin. Lung Cancer, 8, 369-375.
61. Hsu,D.S. et al. (2007) Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J. Clin. Oncol., 25, 4350-4357.
62. Losert,D. et al. (2007) Bcl-2 downregulation sensitizes nonsmall cell lung cancer cells to cisplatin, but not to docetaxel. Anticancer Drugs, 18, 755-761.
63. Tsuzuki,T. et al. (1996) Targeted disruption of the Rad51 gene leads to lethality in embryonic mice. Proc. Natl Acad. Sci. USA, 93, 6236-6240.
64. Sonoda,E. et al. (1998) Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death. EMBO J., 17 598-608.
65. Slupianek,A. et al. (2002) Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol. Cell. Biol., 22, 4189-4201.
66. Bello,V.E. et al. (2002) Homologous recombinational repair vis-a-vis chlorambucil resistance in chronic lymphocytic leukemia. Biochem. Pharmacol., 63, 1585-1588.
67. Ito,M. et al. (2005) Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J. Gene Med., 7 1044-1052.
68. Russell,J.S. et al. (2003) Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res., 63, 7377-7383.
69. Hansen,L.T. et al. (2003) The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer. Int. J. Cancer, 105, 472-479.
70. Wachters,F.M. et al. (2005) ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer, 50, 211-219.
71. Arias-Lopez,C. et al. (2006) p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene. EMBO Rep., 7, 219-224.
72. Lazaro-Trueba,I. et al. (2006) Double bolt regulation of Rad51 by p53: A role for transcriptional repression. Cell Cycle, 5, 1062-1065.
73. Bindra,R.S. et al. (2007) Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia. Oncogene, 26, 2048-2057.
74. Shen,W.H. et al. (2007) Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell, 128, 157-170.